682 related articles for article (PubMed ID: 18268285)
41. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G
Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
[TBL] [Abstract][Full Text] [Related]
42. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Steidl U; Fenk R; Bruns I; Neumann F; Kondakci M; Hoyer B; Gräf T; Rohr UP; Bork S; Kronenwett R; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jan; 35(1):33-6. PubMed ID: 15531906
[TBL] [Abstract][Full Text] [Related]
43. Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.
Baars JW; Holtkamp MJ; Nooyen WJ; Walll EV; Te Velde A; Dalesio O; Slaper-Cortenbach IC; Schoot EV; Richel DJ; Gerritsen WR; Schornagel JH; Rodenhuis S
Anticancer Res; 1996; 16(5B):3089-95. PubMed ID: 8920773
[TBL] [Abstract][Full Text] [Related]
44. Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies.
Fritsch P; Schwinger W; Schwantzer G; Lackner H; Sovinz P; Wendelin G; Benesch M; Sipurzynski S; Urban C
Pediatr Blood Cancer; 2010 Jan; 54(1):134-7. PubMed ID: 19785023
[TBL] [Abstract][Full Text] [Related]
45. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
46. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
47. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
[TBL] [Abstract][Full Text] [Related]
48. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
49. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
50. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG
Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
[TBL] [Abstract][Full Text] [Related]
51. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Mabed M; Al-Kgodary T
Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
[TBL] [Abstract][Full Text] [Related]
52. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
53. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
[TBL] [Abstract][Full Text] [Related]
54. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
[TBL] [Abstract][Full Text] [Related]
55. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
56. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
57. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.
Gerds A; Fox-Geiman M; Dawravoo K; Rodriguez T; Toor A; Smith S; Kiley K; Fletcher-Gonzalez D; Hicks C; Stiff P
Biol Blood Marrow Transplant; 2010 May; 16(5):678-85. PubMed ID: 20045479
[TBL] [Abstract][Full Text] [Related]
58. Effective progenitor cell mobilization in lymphoproliferative disorders using ifosfamide, epirubicin and etoposide (IEV).
O'Connell N; Gardiner N; Duggan C; Enright H; Kennedy MJ; McCann SR; Daly PA; Browne PV
Eur J Haematol Suppl; 2001 Jul; 64():33-6. PubMed ID: 11486399
[TBL] [Abstract][Full Text] [Related]
59. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
[TBL] [Abstract][Full Text] [Related]
60. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]